Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities
Immuno-Oncology and Technology · 2024-03 · 21 · 100704
DOI: 10.1016/j.iotech.2024.100704 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immuno-Oncology and Technology, 2024-03. Verfasst von J McKenzie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Melbourne, Australia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Ipsen.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have become a cornerstone of treatment for many solid organ malignancies. Alongside increasing use, the occurrence of immune-related adverse events (irAEs) has also increased and remains a significant challenge when treating patients with ICI. The underlying pathophysiology of irAE development for many organ systems is yet to be elucidated, but may involve unmasking of latent autoimmunity, increased T-cell recognition of shared antigens on cancer and normal tissue and ICI-triggered immune dysregulation with overactivation of proinflammatory pathways and suppression of immune control pathways. Management strategies for irAEs have historically been borrowed from paradigms for conventional autoimmune conditions such as inflammatory bowel disease and autoimmune hepatitis; however, recent translational efforts have clearly demonstrated key differences in underlying immune signalling pathways. As we begin to understand these differences, we must adapt a more targeted approach to immunosuppression and exercise a more nuanced approach with the multiple biologic agents available to mitigate ICI-related toxicity without reversing the antitumour effect of ICI. In this review, we focus on three key immune-related toxicities where recent clinical and translational work has provided nuanced insights into pathogenesis and treatment strategies: enterocolitis, hepatitis and cardiovascular toxicity including myocarditis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Melbourne, Australia.
- Department of Gastroenterology, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Australia.
- Department of Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Baker Heart and Diabetes Institute, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.
Förderung
- Bristol-Myers Squibb
- Ipsen
Zitieren
APA
McKenzie, J., Sneath, E., Trinh, A., Nolan, M., & Spain, L. (2024). Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. Immuno-Oncology and Technology, 21, 100704. https://doi.org/10.1016/j.iotech.2024.100704
Vancouver
McKenzie J, Sneath E, Trinh A, Nolan M, Spain L. Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. Immuno-Oncology and Technology. 2024;21:100704. doi:10.1016/j.iotech.2024.100704
BibTeX
@article{McKenzie2024,
author = {McKenzie, J and Sneath, E and Trinh, A and Nolan, M and Spain, L},
title = {Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities},
journal = {Immuno-Oncology and Technology},
year = {2024},
volume = {21},
pages = {100704},
doi = {10.1016/j.iotech.2024.100704}
}
EUVIMED